SCHEMBL31359007

SCHEMBL31359007

C[C@H](NC(=O)Cn1c(=O)[nH]c2cc(F)ccc2c1=O)c1ccc(F)cc1F

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GPR139 Q6DWJ6 12/20 0.52
▸ FEN1 P39748 1/20 0.45
▸ ALDH1A1 P00352 4/20 0.44
▸ GAA P10253 4/20 0.44
▸ KDM4E B2RXH2 3/20 0.44
▸ GLA P06280 2/20 0.44
▸ HPGD P15428 2/20 0.44
▸ HSD17B10 Q99714 2/20 0.44
▸ POLB P06746 3/20 0.43
▸ NPC1 O15118 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ HTT P42858 2/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ PKM P14618 1/20 0.39
▸ KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31359031 0.93 GPR139 (0.48) GPR139ALDH1A1GAAKDM4EGLA
SCHEMBL31359130 0.92 GPR139 (0.51) GPR139ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL31359091 0.92 GPR139 (0.51) GPR139ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL31160993 0.92 GPR139 (0.51) GPR139ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL31358999 0.92 GPR139 (0.52) GPR139FEN1HTTKMT2A
SCHEMBL31359027 0.92 GPR139 (0.51) GPR139ALDH1A1GAAKDM4EGLA
SCHEMBL31359054 0.92 GPR139 (0.47) GPR139ALDH1A1GAAKDM4EGLA
SCHEMBL31359110 0.88 GPR139 (0.51) GPR139
SCHEMBL31359099 0.88 GPR139 (0.55) GPR139FEN1ALDH1A1HPGDPOLB
SCHEMBL31160829 0.87 GPR139 (0.48) GPR139FEN1ALDH1A1KDM4EPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559464-B2 Quinazolinone dione compounds and uses thereof EDGEWISE THERAPEUTICS, INC. (US) 2026-02-24 — — US disclosed
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF EDGEWISE THERAPEUTICS, INC. 2025-01-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250026726-A1 QUINAZOLINONE DIONE COMPOUNDS AND USES THEREOF TNNI3, TNNT2, MYLK2 GPR139 4045/4885FEN1 3928/4885ALDH1A1 1640/4885
US-12559464-B2 Quinazolinone dione compounds and uses thereof TNNI3, TNNT2, TNNC1 GPR139 3566/4885FEN1 3297/4885ALDH1A1 1070/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback